|Bid||104.45 x 3000|
|Ask||115.00 x 800|
|Day's range||109.11 - 112.20|
|52-week range||77.69 - 181.07|
|Beta (5Y monthly)||0.50|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
REDWOOD CITY, Calif., July 13, 2021--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2021 after market close on Thursday, August 5, 2021. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
REDWOOD CITY, Calif., Jun 22, 2021--Guardant Health, Inc. (Nasdaq: GH) adds two new products to its portfolio to help improve the management of patients with late-stage and metastatic cancers. The Guardant360 Response™ test represents a breakthrough as the first commercially available, blood-only, liquid biopsy test that detects changes in circulating tumor DNA (ctDNA) levels to provide oncologists an early indication of a patient’s response to treatment. The Guardant360 TissueNext™ test, the co
REDWOOD CITY, Calif., Jun 19, 2021--Please replace the release dated April 30, 2021, with the following corrected version due to changes in the fifth paragraph.